Publications by authors named "YunJu Bae"

Claim this Profile
L
Long-Term Efficacy and Safety of CT-P42 in Patients with Diabetic Macular Edema: 52-Week Results from a Phase 3 Randomized Clinical Trial.
David M Brown, Sebastian Wolf, Milan Veselovsky, Miroslav Veith, Andras Papp, YunJu Bae, Youngmin Bae

Ophthalmol Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study.
Mark G Lebwohl, John Y Koo, Janusz Jaworski, Jakub Trefler, Stefan Daniluk, YunJu Bae

Adv Ther· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY).
Jean-Frederic Colombel, William J Sandborn, Stefan Schreiber, Silvio Danese, Maria Kłopocka, Yunju Bae

J Crohns Colitis· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of CT-P39, an omalizumab biosimilar, in chronic spontaneous urticaria: 16-week follow-up study.
Clive Grattan, Yevgeniya Dytyatkovska, Michał Springer, Maria Ratkova, Borislava Krusheva, Yunju Bae

Clin Transl Allergy· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Usability, efficacy, and safety of candidate tocilizumab biosimilar CT-P47 self-administration via auto-injector and pre-filled syringe in patients with rheumatoid arthritis: a single-arm, open-label, phase 3 study.
Gerd Burmester, Piotr Adrian Klimiuk, Jakub Trefler, Janusz Jaworski, SungHyun Kim, YunJu Bae

Expert Rev Clin Immunol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study.
Mark G Lebwohl, John Y Koo, Janusz Jaworski, Jakub Trefler, Stefan Daniluk, YunJu Bae

Adv Ther· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Safety of Intravenous Candidate Biosimilar CT-P47 and Reference Tocilizumab: A Randomized, Double-Blind, Phase 1 Study.
Miwa Haranaka, Takashi Eto, Takanori Tanaka, Rie Yazawa, Gerd Burmester, YunJu Bae

J Clin Pharmacol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and safety of CT‑P39 via auto-injector are comparable to reference omalizumab via pre-filled syringe.
Tomoko Hasunuma, Clive Grattan, Takashi Eto, Michio Yagi, Rie Yazawa, Yunju Bae

Immunotherapy· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY).
Stephen B Hanauer, Bruce E Sands, Stefan Schreiber, Silvio Danese, Maria Kłopocka, Yunju Bae

Gastroenterology· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47.
Josef S Smolen, Jakub Trefler, Artur Racewicz, Janusz Jaworski, Agnieszka Zielińska, YunJu Bae

RMD Open· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT‑P41 and reference denosumab in healthy males.
Anhye Kim, Jang Hee Hong, Wonsuk Shin, Hyounggyoon Yoo, Jin-Gyu Jung, YunJu Bae

Expert Opin Biol Ther· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study.
Kyung-Sang Yu, Hyunwook Ryu, Dongseong Shin, MinKyu Park, JunGi Hwang, YunJu Bae, JiHun Bae

Expert Opin Biol Ther· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study.
Kim A Papp, Mark G Lebwohl, Diamant Thaçi, Janusz Jaworski, Bartlomiej Kwiek, Yunju Bae

BioDrugs· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study.
Kyung-Sang Yu, Byungwook Kim, Dongseong Shin, Min Kyu Park, Jun Gi Hwang, YunJu Bae, JiHun Bae

Expert Opin Investig Drugs· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and safety of CT-P17 (40 mg/0.4 ml) versus reference adalimumab: randomized study in healthy Japanese adults.
Miwa Haranaka, Takanori Tanaka, SungHyun Kim, YunJu Bae, DaBee Jeon

Immunotherapy· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study.
Won Park, Dae Hyun Yoo, Pedro Miranda, Marek Brzosko, Piotr Wiland, YunJu Bae

Ann Rheum Dis· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Galangin attenuates mast cell-mediated allergic inflammation.
Hui-Hun Kim, Yunju Bae, Sang-Hyun Kim

Food Chem Toxicol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chrysin suppresses mast cell-mediated allergic inflammation: involvement of calcium, caspase-1 and nuclear factor-κB.
Yunju Bae, Soyoung Lee, Sang-Hyun Kim

Toxicol Appl Pharmacol· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toxic effects of mercuric sulfide on immune organs in mice.
Hee-Young Son, Soyoung Lee, Seung-Bin Park, Mi-Sun Kim, Eun-Ju Choi, Yunju Bae, Moon-Chang Baek

Immunopharmacol Immunotoxicol· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis